DK3216793T3 - Triazinforbindelser som p13-kinase- og mtor-inhibitorer - Google Patents

Triazinforbindelser som p13-kinase- og mtor-inhibitorer Download PDF

Info

Publication number: DK3216793T3
Authority: DK; Denmark
Prior art keywords: kinase; mtor inhibitors; triazine compounds; triazine; mtor
Prior art date: 2008-05-23

Application number

DK17162947.0T

Other languages

English (en)

Inventor

Aranapakam M Venkatesan

Zecheng Chen

Christoph M Dehnhardt

Santos Osvaldo Dos

Santos Efren Guillermo Delos

Arie Zask

Jeroen C Verheijen

Joshua Aaron Kaplan

David J Richard

Semiramis Ayral-Kaloustian

Tarek S Mansour

Ariamala Gopalsamy

Kevin J Curran

Mengxiao Shi

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-23

Filing date

2009-05-21

Publication date

2019-05-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3216793(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-21 Application filed by Wyeth Llc filed Critical Wyeth Llc

2019-05-06 Application granted granted Critical

2019-05-06 Publication of DK3216793T3 publication Critical patent/DK3216793T3/da

Links

229940043355 kinase inhibitor Drugs 0.000 title 1
229940124302 mTOR inhibitor Drugs 0.000 title 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
150000003918 triazines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Dermatology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK17162947.0T 2008-05-23 2009-05-21 Triazinforbindelser som p13-kinase- og mtor-inhibitorer DK3216793T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5566108P	2008-05-23	2008-05-23
EP09751541.5A EP2294072B1 (en)	2008-05-23	2009-05-21	Triazine compounds as p13 kinase and mtor inhibitors

Publications (1)

Publication Number	Publication Date
DK3216793T3 true DK3216793T3 (da)	2019-05-06

Family

ID=40911929

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK09751541.5T DK2294072T3 (da)	2008-05-23	2009-05-21	Triazinforbindelser som P13-kinase- og mTOR-inhibitorer
DK17162947.0T DK3216793T3 (da)	2008-05-23	2009-05-21	Triazinforbindelser som p13-kinase- og mtor-inhibitorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK09751541.5T DK2294072T3 (da)	2008-05-23	2009-05-21	Triazinforbindelser som P13-kinase- og mTOR-inhibitorer

Country Status (43)

Country	Link
US (8)	US8039469B2 (da)
EP (3)	EP2294072B1 (da)
JP (2)	JP2011520979A (da)
KR (1)	KR101331341B1 (da)
CN (2)	CN102036995B (da)
AP (2)	AP2775A (da)
AR (2)	AR071909A1 (da)
AU (2)	AU2009248993C1 (da)
BR (1)	BRPI0912294B8 (da)
CA (2)	CA2721710A1 (da)
CL (2)	CL2009001273A1 (da)
CO (1)	CO6311070A2 (da)
CR (1)	CR11757A (da)
CU (1)	CU23887B1 (da)
CY (2)	CY1118879T1 (da)
DK (2)	DK2294072T3 (da)
DO (1)	DOP2010000315A (da)
EA (1)	EA020317B1 (da)
EC (2)	ECSP10010624A (da)
ES (2)	ES2728163T3 (da)
GE (1)	GEP20125589B (da)
HR (2)	HRP20170637T1 (da)
HU (1)	HUE043331T2 (da)
IL (2)	IL209060A (da)
LT (2)	LT3216793T (da)
MA (1)	MA32319B1 (da)
ME (1)	ME01111B (da)
MX (1)	MX2010012808A (da)
MY (1)	MY155653A (da)
NI (1)	NI201000198A (da)
NZ (1)	NZ588526A (da)
PA (2)	PA8828201A1 (da)
PE (2)	PE20091943A1 (da)
PL (1)	PL3216793T3 (da)
PT (2)	PT2294072T (da)
RS (2)	RS58724B1 (da)
SA (1)	SA109300314B1 (da)
SI (2)	SI2294072T1 (da)
TR (1)	TR201906123T4 (da)
TW (2)	TW201008949A (da)
UA (1)	UA99361C2 (da)
WO (2)	WO2009143313A1 (da)
ZA (1)	ZA201007204B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10022381B2 (en) *	2008-05-23	2018-07-17	Pfizer Inc.	Triazine compounds as PI3 kinase and mTOR inhibitors
JP5351254B2 (ja)	2008-05-23	2013-11-27	ノバルティスアーゲー	キノキサリン−およびキノリン−カルボキシアミド誘導体
AU2009248993C1 (en) *	2008-05-23	2013-10-03	Wyeth Llc	Triazine compounds as PI3 kinase and mTOR inhibitors
GB2465405A (en) *	2008-11-10	2010-05-19	Univ Basel	Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010096619A1 (en) *	2009-02-23	2010-08-26	Wyeth Llc	Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
AU2010229468A1 (en)	2009-03-27	2011-10-13	Vetdc, Inc.	Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
UY32582A (es)	2009-04-28	2010-11-30	Amgen Inc	Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
US8486939B2 (en)	2009-07-07	2013-07-16	Pathway Therapeutics Inc.	Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
BR112012003661A2 (pt) *	2009-08-19	2017-04-25	Ambit Biosciences Corp	"compostos de biarila e métodos de uso dos mesmos."
WO2011087812A1 (en) *	2009-12-21	2011-07-21	Vanderbilt University	Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective m1 agonists and methods of making and using same
JP2013521002A (ja)	2010-03-05	2013-06-10	プレジデントアンドフェロウズオブハーバードカレッジ	誘導樹状細胞組成物及びその使用
GB201004200D0 (en) *	2010-03-15	2010-04-28	Univ Basel	Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US9481670B2 (en) *	2011-01-25	2016-11-01	Sphaera Pharma Pte. Ltd.	Triazine compounds
EA201300867A1 (ru) *	2011-01-27	2014-03-31	Дзе Трастиз Оф Принстон Юнивесити	ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
RU2013138835A (ru) *	2011-02-09	2015-03-20	Ф. Хоффманн-Ля Рош Аг	Гетероциклические соединения в качестве ингибиторов pi3 киназы
EP2691384B1 (en)	2011-03-28	2016-10-26	MEI Pharma, Inc.	(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN102250065B (zh) *	2011-05-20	2015-05-13	浙江海正药业股份有限公司	取代的三嗪苯脲衍生物及其用途
CN102887867B (zh) *	2011-07-21	2015-04-15	中国科学院上海药物研究所	一类三嗪类化合物、该化合物的制备方法及其用途
CA2849189A1 (en) *	2011-09-21	2013-03-28	Cellzome Limited	Morpholino substituted urea or carbamate derivatives as mtor inhibitors
JP5995977B2 (ja)	2011-10-07	2016-09-21	セルゾームリミテッド	Ｍｔｏｒ阻害剤としてのモルホリノ置換二環式ピリミジン尿素またはカルバメート誘導体
CN102659765B (zh) *	2011-12-31	2014-09-10	沈阳药科大学	嘧啶及三嗪类化合物的制备方法和应用
EP2852661A1 (en)	2012-05-23	2015-04-01	F. Hoffmann-La Roche AG	Compositions and methods of obtaining and using endoderm and hepatocyte cells
WO2014005182A1 (en) *	2012-07-04	2014-01-09	Monash University	Phosphoinositide 3-kinase (pi3k) inhibitors
US9630958B2 (en)	2012-07-23	2017-04-25	Sphaera Pharma Pte. Ltd.	Triazine compounds
GB201309807D0 (en)	2013-05-31	2013-07-17	Pharma Mar Sau	Antibody drug conjugates
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
ES2834927T3 (es)	2014-03-14	2021-06-21	Pfizer	Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
US20170273922A1 (en) *	2014-10-03	2017-09-28	The Royal Institution For The Advacement Of Learning/Mcgill University	Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
WO2016055907A1 (en) *	2014-10-10	2016-04-14	Pfizer Inc.	Synergistic auristatin combinations
CN107428730B (zh)	2014-11-20	2020-10-16	科学与工业研究会	作为抗癌试剂的1,3,5-三嗪基pi3k抑制剂及其制备方法
PL3233054T3 (pl) *	2014-12-17	2021-12-20	Pfizer Inc.	Postacie użytkowe inhibitora PI3K/MTOR do podawania dożylnego
CN104725361B (zh) *	2015-04-09	2017-05-31	江苏富比亚化学品有限公司	一种受阻胺类光稳定剂3346的制备方法
CN109311825B (zh)	2016-05-12	2022-03-22	南京世其医药科技有限公司	2,4,6-三取代均三嗪化合物及其制备方法和应用
KR102472461B1 (ko)	2016-05-18	2022-11-30	토르쿠르 아게	신경 질환의 치료
US11332480B2 (en)	2017-04-27	2022-05-17	Pharma Mar, S.A.	Antitumoral compounds
IT201700047189A1 (it) *	2017-05-02	2018-11-02	Fondazione St Italiano Tecnologia	Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
CA3063976A1 (en)	2017-05-23	2018-11-29	Mei Pharma, Inc.	Combination therapy
WO2019036489A1 (en)	2017-08-14	2019-02-21	Mei Pharma, Inc.	COMBINATION THERAPY
ES2895370T3 (es)	2017-08-25	2022-02-21	Pfizer	Formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
CN108191837A (zh) *	2018-01-10	2018-06-22	贵州医科大学	PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
KR102022323B1 (ko) *	2018-03-30	2019-09-18	정하윤	트리아진 화합물 및 이의 용도
SI3810089T1 (sl) *	2018-06-07	2023-11-30	Pfizer Inc.	Vodna formulacija,ki vsebuje 1-(4-((4-(dimetilamino)piperidin-1-il)karbonil)fenil)-3-(4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil)sečnino
IL314362A (en)	2018-06-15	2024-09-01	Janssen Pharmaceutica Nv	Rapamycin analogs and their uses
CA3124330A1 (en)	2018-12-21	2020-06-25	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
CN109942562B (zh) *	2019-02-27	2022-02-08	江西科技师范大学	含芳基结构的五元杂环联三嗪类化合物及其制备方法和应用
BR112022010754A2 (pt)	2019-12-05	2022-08-23	Anakuria Therapeutics Inc	Análogos de rapamicina e usos dos mesmos
WO2021207024A1 (en) *	2020-04-07	2021-10-14	Mei Pharma, Inc.	Preparation of a 1,3,5-triazinyl benzimidazole
JP2024504378A (ja) *	2021-01-25	2024-01-31	アトスセラピューティクス，インコーポレイテッド	トリアジン化合物ならびにこれを作製する方法および使用する方法
KR20220138575A (ko)	2021-04-06	2022-10-13	부산대학교병원	전좌 신장암 치료 또는 예방용 약물 스크리닝 방법
CN113200969B (zh) *	2021-05-19	2022-11-25	中国药科大学	一种PI3Kα选择性抑制剂及其制备方法和应用
CA3227191A1 (en)	2021-07-26	2023-02-02	Celcuity Inc.	1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
CN115109049B (zh) *	2022-08-12	2023-08-15	江西科技师范大学	含芳基脲结构的三嗪类化合物及其应用
CN115557908B (zh) *	2022-09-28	2024-10-15	九江学院	一种含硫连接键的三嗪类衍生物及其合成方法、用途
CN116102545B (zh) *	2023-02-01	2025-03-25	贵州医科大学	一种二芳基脲类PI3K/mTOR/HDAC多靶点抑制剂及其药物组合物和应用
CN116239580B (zh) *	2023-03-06	2025-05-23	中国药科大学	三嗪类化合物及其制备方法、药物组合物和应用
WO2025116280A1 (ko) *	2023-11-29	2025-06-05	주식회사 펩토이드	새로운 대칭형 플루오로트리아진 화합물 및 이들의 의학적 또는 생물학적 용도
WO2025128712A1 (en)	2023-12-12	2025-06-19	Celcuity Inc.	Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
WO2026044119A1 (en)	2024-08-21	2026-02-26	Celcuity Inc.	Treatment regimens for gedatolisib in hormonally-driven disorders
GB202415232D0 (en)	2024-10-16	2024-11-27	Nacamed As	Composition
CN120004875A (zh) *	2025-04-22	2025-05-16	中国药科大学	靶向降解磷脂酰肌醇3-激酶的化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1129597C (zh) *	1997-07-24	2003-12-03	全药工业株式会社	杂环化合物和以其为有效成分的抗肿瘤剂
AU1818599A (en) *	1997-12-12	1999-07-05	Abbott Laboratories	Triazine angiogenesis inhibitors
US7071189B2 (en) *	2001-04-27	2006-07-04	Zenyaku Kogyo Kabushiki Kaisha	Heterocyclic compound and antitumor agent containing the same as active ingredient
GB0512324D0 (en) *	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
JP2008531537A (ja)	2005-02-25	2008-08-14	クドスファーマシューティカルズリミテッド	化合物
JP5534811B2 (ja)	2006-08-24	2014-07-02	アストラゼネカアクチボラグ	増殖性疾患の治療に有用なモルホリノピリミジン誘導体
AU2009248993C1 (en) *	2008-05-23	2013-10-03	Wyeth Llc	Triazine compounds as PI3 kinase and mTOR inhibitors

2009
- 2009-05-21 AU AU2009248993A patent/AU2009248993C1/en active Active
- 2009-05-21 MY MYPI2010005448A patent/MY155653A/en unknown
- 2009-05-21 RS RS20190552A patent/RS58724B1/sr unknown
- 2009-05-21 WO PCT/US2009/044774 patent/WO2009143313A1/en not_active Ceased
- 2009-05-21 UA UAA201013896A patent/UA99361C2/uk unknown
- 2009-05-21 WO PCT/US2009/044784 patent/WO2009143317A1/en not_active Ceased
- 2009-05-21 CN CN200980118848.1A patent/CN102036995B/zh active Active
- 2009-05-21 LT LTEP17162947.0T patent/LT3216793T/lt unknown
- 2009-05-21 EP EP09751541.5A patent/EP2294072B1/en active Active
- 2009-05-21 CA CA2721710A patent/CA2721710A1/en not_active Abandoned
- 2009-05-21 ME MEP-2010-188A patent/ME01111B/me unknown
- 2009-05-21 SI SI200931648A patent/SI2294072T1/sl unknown
- 2009-05-21 HR HRP20170637TT patent/HRP20170637T1/hr unknown
- 2009-05-21 PL PL17162947T patent/PL3216793T3/pl unknown
- 2009-05-21 DK DK09751541.5T patent/DK2294072T3/da active
- 2009-05-21 MX MX2010012808A patent/MX2010012808A/es active IP Right Grant
- 2009-05-21 EP EP17162947.0A patent/EP3216793B1/en active Active
- 2009-05-21 CN CN201410412345.8A patent/CN104230831B/zh active Active
- 2009-05-21 PT PT97515415T patent/PT2294072T/pt unknown
- 2009-05-21 CA CA2721692A patent/CA2721692C/en active Active
- 2009-05-21 AP AP2010005453A patent/AP2775A/xx active
- 2009-05-21 JP JP2011510698A patent/JP2011520979A/ja not_active Withdrawn
- 2009-05-21 EA EA201071232A patent/EA020317B1/ru unknown
- 2009-05-21 SI SI200931969T patent/SI3216793T1/sl unknown
- 2009-05-21 NZ NZ588526A patent/NZ588526A/xx unknown
- 2009-05-21 PT PT17162947T patent/PT3216793T/pt unknown
- 2009-05-21 TR TR2019/06123T patent/TR201906123T4/tr unknown
- 2009-05-21 ES ES17162947T patent/ES2728163T3/es active Active
- 2009-05-21 AP AP2010005452A patent/AP2010005452A0/xx unknown
- 2009-05-21 DK DK17162947.0T patent/DK3216793T3/da active
- 2009-05-21 BR BRPI0912294A patent/BRPI0912294B8/pt active IP Right Grant
- 2009-05-21 ES ES09751541.5T patent/ES2625467T3/es active Active
- 2009-05-21 EP EP09751545A patent/EP2300483A1/en not_active Withdrawn
- 2009-05-21 GE GEAP200912011A patent/GEP20125589B/en unknown
- 2009-05-21 KR KR1020107026145A patent/KR101331341B1/ko active Active
- 2009-05-21 LT LTEP09751541.5T patent/LT2294072T/lt unknown
- 2009-05-21 AU AU2009248997A patent/AU2009248997A1/en not_active Abandoned
- 2009-05-21 RS RS20170476A patent/RS55960B1/sr unknown
- 2009-05-21 JP JP2011510697A patent/JP4948677B2/ja not_active Expired - Fee Related
- 2009-05-21 HU HUE17162947A patent/HUE043331T2/hu unknown
- 2009-05-22 CL CL2009001273A patent/CL2009001273A1/es unknown
- 2009-05-22 CL CL2009001274A patent/CL2009001274A1/es unknown
- 2009-05-22 US US12/470,521 patent/US8039469B2/en active Active
- 2009-05-22 US US12/470,525 patent/US20090304692A1/en not_active Abandoned
- 2009-05-23 SA SA109300314A patent/SA109300314B1/ar unknown
- 2009-05-25 PE PE2009000724A patent/PE20091943A1/es active IP Right Grant
- 2009-05-25 TW TW098117318A patent/TW201008949A/zh unknown
- 2009-05-25 PA PA20098828201A patent/PA8828201A1/es unknown
- 2009-05-25 TW TW098117331A patent/TWI389906B/zh active
- 2009-05-25 PE PE2009000725A patent/PE20091957A1/es not_active Application Discontinuation
- 2009-05-25 PA PA20098828101A patent/PA8828101A1/es unknown
- 2009-05-26 AR ARP090101879A patent/AR071909A1/es not_active Application Discontinuation
- 2009-05-26 AR ARP090101878A patent/AR071908A1/es active IP Right Grant
2010
- 2010-10-08 ZA ZA2010/07204A patent/ZA201007204B/en unknown
- 2010-10-21 DO DO2010000315A patent/DOP2010000315A/es unknown
- 2010-10-26 CR CR11757A patent/CR11757A/es unknown
- 2010-11-01 IL IL209060A patent/IL209060A/en active IP Right Grant
- 2010-11-01 IL IL209061A patent/IL209061A0/en unknown
- 2010-11-18 NI NI201000198A patent/NI201000198A/es unknown
- 2010-11-19 CO CO10145581A patent/CO6311070A2/es active IP Right Grant
- 2010-11-22 EC EC2010010624A patent/ECSP10010624A/es unknown
- 2010-11-22 EC EC2010010623A patent/ECSP10010623A/es unknown
- 2010-11-23 CU CU20100229A patent/CU23887B1/es active IP Right Grant
- 2010-11-23 MA MA33370A patent/MA32319B1/fr unknown
2011
- 2011-08-26 US US13/218,571 patent/US8217036B2/en active Active
2012
- 2012-06-06 US US13/490,309 patent/US8445486B2/en active Active
- 2012-12-18 US US13/718,928 patent/US8575159B2/en active Active
2013
- 2013-07-25 US US13/950,584 patent/US8748421B2/en active Active
2014
- 2014-04-23 US US14/259,414 patent/US8859542B2/en active Active
- 2014-09-04 US US14/477,650 patent/US9174963B2/en active Active
2017
- 2017-05-03 CY CY20171100482T patent/CY1118879T1/el unknown
2019
- 2019-04-10 HR HRP20190680TT patent/HRP20190680T1/hr unknown
- 2019-04-16 CY CY20191100421T patent/CY1121699T1/el unknown

Also Published As

Publication number	Publication date
KR101331341B1 (ko)	2013-11-19
MA32319B1 (fr)	2011-05-02
EP3216793B1 (en)	2019-03-27
MY155653A (en)	2015-11-13
JP2011520979A (ja)	2011-07-21
ES2625467T3 (es)	2017-07-19
HRP20170637T1 (hr)	2017-06-30
NI201000198A (es)	2011-05-09
WO2009143317A1 (en)	2009-11-26
DOP2010000315A (es)	2010-12-15
PL3216793T3 (pl)	2019-09-30
US20110312955A1 (en)	2011-12-22
EP3216793A1 (en)	2017-09-13
IL209060A (en)	2014-05-28
PT2294072T (pt)	2017-05-29
EP2294072A1 (en)	2011-03-16
US9174963B2 (en)	2015-11-03
CL2009001274A1 (es)	2009-10-16
CA2721692A1 (en)	2009-11-26
LT2294072T (lt)	2017-06-12
US20140248239A1 (en)	2014-09-04
US8039469B2 (en)	2011-10-18
SA109300314B1 (ar)	2012-09-26
US20130315865A1 (en)	2013-11-28
UA99361C2 (uk)	2012-08-10
PA8828101A1 (es)	2009-12-16
CN102036995B (zh)	2014-09-17
CY1118879T1 (el)	2018-01-10
WO2009143313A1 (en)	2009-11-26
LT3216793T (lt)	2019-05-10
ECSP10010624A (es)	2010-12-30
EP2294072B1 (en)	2017-03-29
HUE043331T2 (hu)	2019-08-28
US8575159B2 (en)	2013-11-05
SI2294072T1 (sl)	2017-05-31
PE20091943A1 (es)	2009-12-19
US8859542B2 (en)	2014-10-14
BRPI0912294B8 (pt)	2021-05-25
SI3216793T1 (sl)	2019-06-28
AP2775A (en)	2013-09-30
CN102036995A (zh)	2011-04-27
RS55960B1 (sr)	2017-09-29
MX2010012808A (es)	2010-12-21
BRPI0912294A2 (pt)	2015-10-20
PT3216793T (pt)	2019-05-30
IL209061A0 (en)	2011-01-31
AU2009248993C1 (en)	2013-10-03
CR11757A (es)	2010-11-30
JP2011522802A (ja)	2011-08-04
BRPI0912294B1 (pt)	2019-11-12
AU2009248993A1 (en)	2009-11-26
PE20091957A1 (es)	2009-12-30
HK1203199A1 (en)	2015-10-23
ES2728163T3 (es)	2019-10-22
CN104230831A (zh)	2014-12-24
AU2009248993B2 (en)	2011-07-07
CN104230831B (zh)	2016-08-24
CU23887B1 (es)	2013-04-19
AR071909A1 (es)	2010-07-21
AP2010005453A0 (en)	2010-12-31
NZ588526A (en)	2012-08-31
US8748421B2 (en)	2014-06-10
RS58724B1 (sr)	2019-06-28
US20130109670A1 (en)	2013-05-02
HRP20190680T1 (hr)	2019-06-14
EA020317B1 (ru)	2014-10-30
GEP20125589B (en)	2012-07-25
US8445486B2 (en)	2013-05-21
KR20110002485A (ko)	2011-01-07
TW201008949A (en)	2010-03-01
US8217036B2 (en)	2012-07-10
EA201071232A1 (ru)	2011-06-30
CA2721692C (en)	2014-01-14
US20090304692A1 (en)	2009-12-10
ZA201007204B (en)	2011-12-28
ECSP10010623A (es)	2010-12-30
AR071908A1 (es)	2010-07-21
HK1157328A1 (en)	2012-06-29
TR201906123T4 (tr)	2019-05-21
CL2009001273A1 (es)	2009-11-27
CU20100229A7 (es)	2011-11-15
CY1121699T1 (el)	2020-07-31
IL209060A0 (en)	2011-01-31
JP4948677B2 (ja)	2012-06-06
EP2300483A1 (en)	2011-03-30
TW201011010A (en)	2010-03-16
US20090291079A1 (en)	2009-11-26
US20130005723A1 (en)	2013-01-03
TWI389906B (zh)	2013-03-21
ME01111B (me)	2013-03-20
AP2010005452A0 (en)	2010-12-31
US20150011752A1 (en)	2015-01-08
PA8828201A1 (es)	2009-12-16
CA2721710A1 (en)	2009-11-26
CO6311070A2 (es)	2011-08-22
AU2009248997A1 (en)	2009-11-26
DK2294072T3 (da)	2017-05-15

Publication	Publication Date	Title
CY2020024I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
CY2019009I1 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
DK2389382T3 (da)	2013-07-08	Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
DK2318389T3 (da)	2013-09-30	Pyridazinderivater som SMO-inhibitorer
BRPI0912294A2 (pt)	2015-10-20	compostos de triazina como inibidores de pi3 quinase e de mtor
DK1926722T3 (da)	2011-12-19	Substituerede benzimidazoler som kinaseinhibitorer
CY2017016I2 (el)	2017-07-12	Αναστολεις πρωτεασωματος
DK2470546T3 (da)	2013-10-14	HEXAHYDROOXAZINOPTERIDIN- forbindelser til anvendelse som mTOR INHIBITORER
DK2162131T3 (da)	2013-05-27	Quinolin-derivativer som pi3-kinase-inhibitorer
ATE546444T1 (de)	2012-03-15	Amidophenoxyindazole als c-met-hemmer
BRPI0914789A2 (pt)	2015-10-20	efeitos sinérgicos
DK2139892T3 (da)	2011-12-12	Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK2448938T3 (da)	2014-08-25	Pyrimidinoner som pi3k-inhibitorer
DK2421825T3 (da)	2014-02-03	Azetidinyldiamider som monoacylglycerollipase-inhibitorer
BRPI0921156A2 (pt)	2016-02-23	inibidores de pi3k/mtor quinase
ATE522535T1 (de)	2011-09-15	Pyrrolotriazin-kinasehemmer
DK3354652T3 (da)	2020-05-18	Piperidin-4-yl azetidinderivativer som jak1-inhibitorer
DK2899191T3 (da)	2017-11-13	Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
ATE549340T1 (de)	2012-03-15	Spiroindolinon-derivate als mdm2-p53 inhibitoren
ATE506358T1 (de)	2011-05-15	2-benzylpyridazinonderivate als met-kinasehemmer
SMT201400154B (it)	2015-01-15	Composti di triazolopiridina come inibitori di chinasi pim
ATE519763T1 (de)	2011-08-15	Pyrrolopyrazin-kinasehemmer
DK2414362T3 (da)	2014-09-22	Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
BRPI0912668A2 (pt)	2016-01-26	composto e composições como inibidores de quinase